Commence Sildenafil Cream Phase 2b study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 16 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- March 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Sildenafil Cream, 3.6% Phase 2b to commence in 1Q2021”
What we found
Evidence strength A What the grades mean
The company announced the initiation of the Phase 2b RESPOND clinical trial for Sildenafil Cream, 3.6% in March 2021, which falls within the first quarter of 2021.
-
A Dare Bioscience, Inc. 10-Q filed 2021-05-13
“In March 2021, we announced initiation of our Phase 2b RESPOND clinical trial of Sildenafil Cream, 3.6% in women with FSAD.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Commence
- Deliverable
- Sildenafil Cream Phase 2b study
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Dare Bioscience, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-DARE-023886 · Corrections policy